CN103619825B - 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 - Google Patents
可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 Download PDFInfo
- Publication number
- CN103619825B CN103619825B CN201280030881.0A CN201280030881A CN103619825B CN 103619825 B CN103619825 B CN 103619825B CN 201280030881 A CN201280030881 A CN 201280030881A CN 103619825 B CN103619825 B CN 103619825B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- thiadiazol
- piperazine
- ethyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1c(*NC)*c(*2CC*(*)CC2)[n]1 Chemical compound C*1c(*NC)*c(*2CC*(*)CC2)[n]1 0.000 description 7
- IMGUHIWIBSSTMC-UHFFFAOYSA-N COc1cc(CCC(CC2)CCN2c2nc(-c(cc3F)ccc3F)n[s]2)ccn1 Chemical compound COc1cc(CCC(CC2)CCN2c2nc(-c(cc3F)ccc3F)n[s]2)ccn1 IMGUHIWIBSSTMC-UHFFFAOYSA-N 0.000 description 1
- HQGQUNSFWGWBFG-UHFFFAOYSA-N COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)cc(F)c3F)n[s]2)cc1 Chemical compound COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)cc(F)c3F)n[s]2)cc1 HQGQUNSFWGWBFG-UHFFFAOYSA-N 0.000 description 1
- SXCLTFRQEZSXFQ-UHFFFAOYSA-N COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)ccc3Cl)n[s]2)cn1 Chemical compound COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)ccc3Cl)n[s]2)cn1 SXCLTFRQEZSXFQ-UHFFFAOYSA-N 0.000 description 1
- ZBRVNSDRHKCHPE-UHFFFAOYSA-N COc1cccc(CCN(CC2)CCN2c2nc(-c(ccc(F)c3)c3OC)n[s]2)c1 Chemical compound COc1cccc(CCN(CC2)CCN2c2nc(-c(ccc(F)c3)c3OC)n[s]2)c1 ZBRVNSDRHKCHPE-UHFFFAOYSA-N 0.000 description 1
- WZXLJQFOOKUNSK-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[s]c(N2CCN(Cc3ccc4OCOc4c3)CC2)n1 Chemical compound Cc(cc1)ccc1-c1n[s]c(N2CCN(Cc3ccc4OCOc4c3)CC2)n1 WZXLJQFOOKUNSK-UHFFFAOYSA-N 0.000 description 1
- JEXCGMAHECZNFB-UHFFFAOYSA-N FC(c1ccc(CC[I]2CCC(CC3=[I]C(C(C4)C=NC=C4Cl)=CS3)=CCC2)cc1)(F)F Chemical compound FC(c1ccc(CC[I]2CCC(CC3=[I]C(C(C4)C=NC=C4Cl)=CS3)=CCC2)cc1)(F)F JEXCGMAHECZNFB-UHFFFAOYSA-N 0.000 description 1
- KKZCJEJXBUIJRQ-UHFFFAOYSA-N N#Cc(cc1)ccc1-c1n[s]c(N2CCN(CCc(cc3)ccc3Cl)CC2)n1 Chemical compound N#Cc(cc1)ccc1-c1n[s]c(N2CCN(CCc(cc3)ccc3Cl)CC2)n1 KKZCJEJXBUIJRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172324.3 | 2011-07-01 | ||
| EP11172324 | 2011-07-01 | ||
| PCT/EP2012/062778 WO2013004642A1 (en) | 2011-07-01 | 2012-06-29 | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103619825A CN103619825A (zh) | 2014-03-05 |
| CN103619825B true CN103619825B (zh) | 2015-10-14 |
Family
ID=46545347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280030881.0A Active CN103619825B (zh) | 2011-07-01 | 2012-06-29 | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9023852B2 (https=) |
| EP (1) | EP2726470B1 (https=) |
| JP (1) | JP5972367B2 (https=) |
| CN (1) | CN103619825B (https=) |
| AU (1) | AU2012280420B2 (https=) |
| CA (1) | CA2837247C (https=) |
| ES (1) | ES2540956T3 (https=) |
| PL (1) | PL2726470T3 (https=) |
| WO (1) | WO2013004642A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2744798T3 (pl) | 2011-08-17 | 2016-08-31 | Remynd Nv | Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera |
| WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| AU2017281907B2 (en) * | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| KR102728619B1 (ko) | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| EP3731859B1 (en) | 2017-12-27 | 2025-08-20 | St. Jude Children's Research Hospital, Inc. | Pyridazine compounds for use to treat disorders associated with castor |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2025104092A1 (en) | 2023-11-13 | 2025-05-22 | Remynd N.V. | Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348449A (zh) * | 1999-04-26 | 2002-05-08 | 神经研究公司 | 杂芳基二氮杂环烷烃及其制备方法和应用 |
| CN1349520A (zh) * | 1999-03-03 | 2002-05-15 | 美国家用产品公司 | 用作5－羟色胺能药物的新型二唑衍生物 |
| CN101378757A (zh) * | 2006-02-07 | 2009-03-04 | 瑞敏德股份有限公司 | 治疗神经变性疾病的噻二唑衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004032567A1 (de) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| PE20070099A1 (es) * | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| WO2007092435A2 (en) * | 2006-02-07 | 2007-08-16 | Wyeth | 11-beta hsd1 inhibitors |
-
2012
- 2012-06-29 EP EP20120737238 patent/EP2726470B1/en active Active
- 2012-06-29 CN CN201280030881.0A patent/CN103619825B/zh active Active
- 2012-06-29 ES ES12737238.1T patent/ES2540956T3/es active Active
- 2012-06-29 US US14/127,779 patent/US9023852B2/en active Active
- 2012-06-29 CA CA2837247A patent/CA2837247C/en active Active
- 2012-06-29 AU AU2012280420A patent/AU2012280420B2/en not_active Ceased
- 2012-06-29 JP JP2014517749A patent/JP5972367B2/ja not_active Expired - Fee Related
- 2012-06-29 PL PL12737238T patent/PL2726470T3/pl unknown
- 2012-06-29 WO PCT/EP2012/062778 patent/WO2013004642A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1349520A (zh) * | 1999-03-03 | 2002-05-15 | 美国家用产品公司 | 用作5－羟色胺能药物的新型二唑衍生物 |
| CN1348449A (zh) * | 1999-04-26 | 2002-05-08 | 神经研究公司 | 杂芳基二氮杂环烷烃及其制备方法和应用 |
| CN101378757A (zh) * | 2006-02-07 | 2009-03-04 | 瑞敏德股份有限公司 | 治疗神经变性疾病的噻二唑衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140128404A1 (en) | 2014-05-08 |
| US9023852B2 (en) | 2015-05-05 |
| JP2014518240A (ja) | 2014-07-28 |
| PL2726470T3 (pl) | 2015-09-30 |
| JP5972367B2 (ja) | 2016-08-17 |
| HK1192726A1 (en) | 2014-08-29 |
| CN103619825A (zh) | 2014-03-05 |
| ES2540956T3 (es) | 2015-07-15 |
| CA2837247A1 (en) | 2013-01-10 |
| EP2726470B1 (en) | 2015-04-29 |
| AU2012280420A1 (en) | 2013-12-12 |
| CA2837247C (en) | 2020-03-31 |
| WO2013004642A1 (en) | 2013-01-10 |
| AU2012280420B2 (en) | 2017-01-05 |
| EP2726470A1 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103619825B (zh) | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 | |
| EP1678171B1 (en) | 2-amino-4-thiazolone-pyrimidine derivatives as protein kinase inhibitors | |
| JP5258790B2 (ja) | Ｒｈｏキナーゼインヒビター | |
| US5086053A (en) | Derivatives of 1,3,4-thiadiazole, a method of obtaining them and pharmaceutical compositions containing them | |
| JP2007512230A (ja) | プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物 | |
| MX2007008373A (es) | Derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina y su uso en terapia. | |
| EA024984B1 (ru) | Производные 6-циклоалкил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a | |
| JP2008515992A (ja) | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 | |
| JP2007500178A (ja) | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 | |
| CN108341814B (zh) | Jak激酶抑制剂及其应用 | |
| EP3044223B1 (en) | 2,3-dihydro-1h-inden-1-one derivatives as retinoic acid-related orphan receptor gamma (ror gamma) antagonists for treating multiple sclerosis | |
| CA1284325C (en) | Antipsychotic cyclic imide derivatives of 2-(4- butylpiperazin-1-yl) pyridines | |
| KR20040072649A (ko) | 티아디아졸린 유도체 | |
| US9808456B2 (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease | |
| HK1192726B (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | |
| CN1898237B (zh) | 嘧啶-4-基-3,4-硫酮化合物及其治疗用途 | |
| WO2022129914A1 (en) | Alkyne derivatives as inhibitors of c-abl | |
| HK1192848B (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |